XRTX vs XTLB

XORTX Therapeutics Inc. vs XTL Biopharmaceuticals Ltd. — Valuation Comparison 2026

XRTX

Biotechnology
XORTX Therapeutics Inc.
Quality
3.4
out of 10
Value Trap
Price
$2.26
Last close
Models
7/13
Active
VS

XTLB

Biotechnology
XTL Biopharmaceuticals Ltd.
Quality
1.7
out of 10
Value Trap
Price
$2.46
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType XRTX Fair ValueXRTX Upside XTLB Fair ValueXTLB Upside
Bayesian DCF Intrinsic $4.91 +117.4% $0.65 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $6.57 +190.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $0.72 -71.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for XRTX vs XTLB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XRTX vs XTLB — Which Stock Is More Undervalued?

XRTX scores higher with a 3.4/10 quality rating vs XTLB's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XORTX Therapeutics Inc. (XRTX) and XTL Biopharmaceuticals Ltd. (XTLB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XRTX currently trades at $2.26 with a QOC of 3.4/10, while XTLB trades at $2.46 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).